Giuseppina Li Pira

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.

Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.

Journal: Nature medicine

Published: September 09, 2025

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.

Journal: Nature medicine

Published: August 19, 2025

GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.

GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.

Journal: Nature medicine

Published: March 01, 2025

Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.

Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.

Journal: Blood advances

Published: February 10, 2025

Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation.

Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation.

Journal: Haematologica

Published: July 27, 2024

Antiviral potential of Vδ2 T cells in children given TCR αβ/CD19 cell-depleted HLA-haploidentical HSCT.

Antiviral potential of Vδ2 T cells in children given TCR αβ/CD19 cell-depleted HLA-haploidentical HSCT.

Journal: Blood advances

Published: June 11, 2024

Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.

Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.

Journal: Nature medicine

Published: February 09, 2024

Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with clinical outcomes.

Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with clinical outcomes.

Journal: Haematologica

Published: November 16, 2023

TCRαβ/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis.

TCRαβ/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis.

Journal: Blood

Published: May 30, 2023

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.

Journal: The New England journal of medicine

Published: April 05, 2023

Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.

Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.

Journal: Blood

Published: February 06, 2023

αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes.

αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes.

Journal: Haematologica

Published: January 20, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026